BNT327

Phase 2Small molecule

BioNTech

BNT327 is one of 119 small molecule programs targeting Locally Advanced Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

118

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally Advanced Breast CancerRecruiting

Advanced Lung CancerRecruiting

Advanced/metastatic Solid TumorsRecruiting

Non-Small Cell Lung CancerRecruiting

Advanced Solid TumorsRecruiting

Locally Advanced Breast CancerPreclinical

Recruiting

Advanced Lung CancerPreclinical

Recruiting

Advanced/metastatic Solid TumorsPhase 2

Recruiting

Non-Small Cell Lung CancerPhase 2

Recruiting

Advanced Solid TumorsPhase 2

Recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Cytoxan

BBaxter Healthcare Corporation

Phase 3

17 2

KN046

JJiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 3

4 3

Huaier Granule

QQidong Gaitianli Medicines Co., Ltd

Phase 3

3 4

BNT327

BioNTech

Phase 2

1 5

Remeron

OOrganon and Co

Preclinical

1 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 10

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1/2Recruiting

Advanced Solid Tumors

NCT07147348

Q3 2029

PreclinicalRecruiting

Locally Advanced Breast Cancer

NCT06827236

Q2 2030

PreclinicalRecruiting

Non-Small Cell Lung Cancer

NCT07111520

Phase 2Recruiting

Advanced/metastatic Solid Tumors

NCT06953089

Q2 2032

PreclinicalRecruiting

Advanced Lung Cancer

NCT06892548

Clinical

Trials by Indication[1]

Advanced/Metastatic Solid Tumors2 trials

First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

Recruiting·DDualityBio Inc.·Phase 1/2·NCT05438329·1,123 enrolled

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

Recruiting·DDualityBio Inc.·Phase 2·NCT06953089·492 enrolled

Advanced Solid Tumors1 trial

A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors

Recruiting· BioNTech logo

BioNTech·Phase 1/2·NCT07147348·375 enrolled

Locally Advanced Breast Cancer1 trial

A Phase I/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of BNT323 in Combination With BNT327 in Participants With Advanced Breast Cancer

Recruiting· BioNTech logo

BioNTech·Preclinical·NCT06827236·380 enrolled

Advanced Lung Cancer1 trial

A Phase Ib/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Recommended Combination Dose of BNT324 With BNT327 in Participants With Advanced Lung Cancer

Recruiting· BioNTech logo

BioNTech·Preclinical·NCT06892548·594 enrolled

Non-Small Cell Lung Cancer1 trial

A Phase Ib/II, Multi-site, Open-label, Dose Finding Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT326 in Combination With BNT327 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Recruiting· BioNTech logo

BioNTech·Preclinical·NCT07111520·880 enrolled

1 more indication

Metastatic Colorectal Cancer1 trial

A Phase I/II, Randomized, Multi-site Trial to Investigate the Efficacy and Safety of BNT314 in Combination With Pumitamig and Chemotherapy in Participants With Metastatic Colorectal Cancer

Recruiting· BioNTech logo

BioNTech·Preclinical·NCT07079631·482 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for BNT327. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BNT327 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BNT327. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioNTech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BioNTech

BNT327

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q3 2029

Q2 2030

Q2 2032

Trials by Indication[1]

Advanced/Metastatic Solid Tumors2 trials

Advanced Solid Tumors1 trial

Locally Advanced Breast Cancer1 trial

Advanced Lung Cancer1 trial

Non-Small Cell Lung Cancer1 trial

Metastatic Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News